Pioneering new treatments for chronic eye diseases

At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

History & Locations

Focused on overcoming the challenges of conventional glaucoma therapies, Glaukos pioneered micro-invasive glaucoma surgery, or MIGS. In 2012, Glaukos launched the first-ever US-approved MIGS device, the iStent^® Trabecular Micro-Bypass Stent. Glaukos launched its next-generation iStent inject^® device in the United States in 2018. In addition to an abiding focus on glaucoma, Glaukos is broadening its mission to include new aspirations that seek to improve treatment alternatives and quality of life for people suffering with corneal disorders and retinal diseases. Glaukos is seeking to leverage its platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. Learn more about our history and international presence.

More About Our History & Locations

Ophthalmic Innovation

Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. See how our dedicated commitment to continuous innovation has resulted in an unrivaled pipeline of novel therapies.

Learn More

Philanthropy is in our backbone

From financial contributions to product donations, helping the visually impaired and others in need is deeply ingrained in our corporate culture.

Learn About Corporate Giving

Awards & Recognition

We’re honored to be the recipient of multiple industry awards and recognized by major media publications.

Learn More

Corporate Overview

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in 2018 and the iStent inject^® W in 2020.

In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.

Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in San Clemente, California, with additional locations in Waltham and Burlington, Massachusetts.